These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 3755647)

  • 1. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy.
    Valagussa P; Tancini G; Bonadonna G
    Cancer; 1986 Oct; 58(7):1411-7. PubMed ID: 3755647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
    Velez-Garcia E; Moore M; Vogel CL; Marcial V; Ketcham A; Bartolucci A; Liu C; Smalley R
    Breast Cancer Res Treat; 1983; 3 Suppl():S49-60. PubMed ID: 6367861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.
    Bonadonna G; Valagussa P; Rossi A; Tancini G; Brambilla C; Zambetti M; Veronesi U
    Breast Cancer Res Treat; 1985; 5(2):95-115. PubMed ID: 3839424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
    International Breast Cancer Study Group
    J Clin Oncol; 1997 Apr; 15(4):1385-94. PubMed ID: 9193330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
    Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
    J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
    Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
    J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmastectomy radiotherapy and concomitant adjuvant chemotherapy versus adjuvant chemotherapy alone in premenopausal breast cancer patients with positive axillary nodes.
    Micheletti E; La Face B; Huscher A; Catalano G; Ambrosi E; Marini G; Simoncini E
    Tumori; 1998; 84(6):652-8. PubMed ID: 10080670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
    Bonadonna G; Rossi A; Valagussa P; Banfi A; Veronesi U
    Cancer; 1977 Jun; 39(6 Suppl):2904-15. PubMed ID: 326384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
    Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) Trial.
    Vélez-García E; Carpenter JT; Moore M; Vogel CL; Marcial V; Ketcham A; Singh KP; Bass D; Bartolucci AA; Smalley R
    Eur J Cancer; 1992; 28A(11):1833-7. PubMed ID: 1389521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
    J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group.
    Castiglione-Gertsch M; Tattersall M; Hacking A; Goldhirsch A; Gudgeon A; Gelber RD; Lindtner J; Coates A; Collins J; Isley M; Senn HJ; Rudenstam CM
    Eur J Cancer; 1997 Dec; 33(14):2321-5. PubMed ID: 9616275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
    Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
    J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes.
    Valagussa P; Tess JD; Rossi A; Tancini G; Banfi A; Bonadonna G
    Breast Cancer Res Treat; 1981; 1(4):349-56. PubMed ID: 6897368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.